In Depth Analysis

In this +Insight, we examine how CMS is using MA encounter data today, where policymakers may take it next, and what providers, health plans, life sciences companies, and other healthcare stakeholders should be watching as this increasingly important dataset continues to evolve.

Read key takeaways from the proposed rule and access our updated, interactive data dashboard.

Read more to understand how the CMS LEAD Model is structured and what it may mean for providers, payers, and other stakeholders.

This +Insight aims to make sense of the various activities and proposals underway or under consideration that could impact drug prices paid by consumers.